Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 36Cytarabine 32Cyclophosphamide 31Whole-Body Irradiation 30Busulfan 30Tacrolimus 28Mycophenolic Acid 27Methotrexate 18Etoposide 18Cyclosporine 18Antilymphocyte Serum 16Filgrastim 15Melphalan 13Granulocyte Colony-Stimulating Factor 11Idarubicin 10Flow Cytometry 9Clofarabine 9Daunorubicin 8sargramostim 7Radiotherapy 7Mitoxantrone 7Cord Blood Stem Cell Transplantation 7Transplantation 6Thiotepa 6Sirolimus 6merphos 5fludarabine 5aldesleukin 5Vorinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Congenital Abnormalities × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡